Clinical Trials Browser

Phase 2 × Crizotinib × Dermatologic × Clear all

NCT02223819 2023-12-06

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Phase 2 Completed

34 enrolled 9 charts

Uveal Melanoma